Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday

Key Points

• Cardiff Oncology (NASDAQ:CRDF) is expected to release its Q2 2025 earnings results on August 14, with analysts predicting a loss of $0.19 per share and $0.10 million in revenue.
• The company's quarterly earnings report on July 29 revealed a loss of $0.21 EPS, falling short of estimates and reflecting a significant negative net margin.
• Investors are closely watching the stock as recent analyst reports have varied widely, with price targets ranging from $3.50 to $19.00 and a current consensus rating of "Moderate Buy."

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Cardiff Oncology to post earnings of ($0.19) per share and revenue of $0.10 million for the quarter.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. The company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.11 million. On average, analysts expect Cardiff Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cardiff Oncology Price Performance

Shares of NASDAQ:CRDF opened at $2.44 on Thursday. The business has a fifty day moving average price of $3.56 and a 200-day moving average price of $3.47. The company has a market capitalization of $162.33 million, a PE ratio of -2.80 and a beta of 1.54. Cardiff Oncology has a 1-year low of $2.09 and a 1-year high of $5.64.

Analyst Upgrades and Downgrades

CRDF has been the topic of a number of recent analyst reports. HC Wainwright dropped their price target on shares of Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday. Jefferies Financial Group started coverage on shares of Cardiff Oncology in a report on Tuesday, June 24th. They issued a "hold" rating and a $3.50 target price on the stock. LADENBURG THALM/SH SH started coverage on shares of Cardiff Oncology in a research report on Tuesday, July 8th. They issued a "buy" rating and a $19.00 target price for the company. Finally, William Blair reissued an "outperform" rating on shares of Cardiff Oncology in a report on Wednesday, June 18th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Cardiff Oncology presently has a consensus rating of "Moderate Buy" and an average target price of $10.10.

Insider Activity at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace bought 275,000 shares of Cardiff Oncology stock in a transaction dated Wednesday, July 30th. The shares were purchased at an average cost of $2.45 per share, for a total transaction of $673,750.00. Following the acquisition, the director directly owned 1,330,676 shares in the company, valued at approximately $3,260,156.20. This represents a 26.05% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 7.70% of the company's stock.

Hedge Funds Weigh In On Cardiff Oncology

A hedge fund recently raised its stake in Cardiff Oncology stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 50.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,319 shares of the company's stock after purchasing an additional 11,497 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.05% of Cardiff Oncology worth $108,000 at the end of the most recent quarter. 16.29% of the stock is currently owned by institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.